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ABSTRACT
Background Tumour necrosis factor (TNF) is upregulated
in the alveolar space early in the course of ventilator-
induced lung injury (VILI). Studies in genetically modified
mice indicate that the two TNF receptors play opposing
roles during injurious high-stretch mechanical ventilation,
with p55 promoting but p75 preventing pulmonary
oedema.
Aim To investigate the effects of selective inhibition of
intra-alveolar p55 TNF receptor on pulmonary oedema
and inflammation during ventilator-induced lung injury
using a newly developed domain antibody.
Methods Anaesthetised mice were ventilated with high
tidal volume and given an intratracheal bolus of p55-
specific domain antibody or anti-TNF monoclonal
antibody (‘pure’ VILI model). As a model of enhanced
inflammation, a subclinical dose of lipopolysaccharide
(LPS) was included in the intratracheal antibody bolus
(LPS+VILI model). Development of lung injury was
assessed by respiratory mechanics and blood gases and
protein levels in lavage fluid. Flow cytometry was used to
determine leucocyte recruitment and alveolar
macrophage activation, while lavage fluid cytokines were
assessed by ELISA.
Results The ventilation protocol produced deteriorations
in respiratory mechanics and gas exchange with
increased lavage fluid protein levels in the two models.
The p55-specific domain antibody substantially
attenuated all of these changes in the ‘pure‘ VILI model,
while anti-TNF antibody was ineffective. In the LPS+VILI
model, p55 blockade prevented deteriorations in
respiratory mechanics and oxygenation and significantly
decreased neutrophil recruitment, expression of
intercellular adhesion molecule 1 on alveolar
macrophages, and interleukin 6 and monocyte
chemotactic protein 1 levels in lavage fluid.
Conclusions Selective inhibition of intra-alveolar p55
TNF receptor signalling by domain antibodies may open
new therapeutic approaches for ventilated patients with
acute lung injury.
INTRODUCTION
Mechanical ventilation is essential for the treat-
ment of patients with acute lung injury/acute
respiratory distress syndrome (ALI/ARDS),
although this frequently results in the development
of ventilator-induced lung injury (VILI).1 While the
initiating trigger is unique, the ﬁnal pathophysi-
ology of VILI is indistinguishable from that of ALI
of other aetiologiesdthat is, characterised by
pulmonary oedema and inﬂammation.2 3 VILI may
be particularly amenable to early pharmacological
intervention as its iatrogenic nature means that
onset occurs in a predictable manner and within
the hospital setting.
The proinﬂammatory cytokine tumour necrosis
factor (TNF) has been consistently implicated in
the pathogenesis of ALI/VILI, both clinically and
in experimental models.3e6 Clinical trials of anti-
TNF therapy in patients with sepsis/ALI7e10 have
unfortunately shown little or no beneﬁts, and in
some cases may have led to increased morbidity.
The reasons behind such a lack of beneﬁt are
unclear, but are likely to include issues relating to
the design of the agents used and also to the
complicated biology of TNF signalling. TNF signals
through two cell surface receptors, p55 and p75,
and recent evidence suggests that signalling
through these individual receptors may have
differentialdeven opposingdroles in a number of
pathological conditions.11e13 We previously found
that biologically active TNF is upregulated within
the alveolar space early during the development of
VILI.14 Moreover, using TNF receptor knock-out
mice, we found that the two receptors of TNF play
opposing roles during VILI: p55 receptor knock-out
mice were protected while p75 receptor knock-out
animals were more susceptible to pulmonary
oedema.15 In light of these data, we propose that
‘selective’ inhibition of ‘p55 TNF receptor ’
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signalling, speciﬁcally within the alveolar space, would be clin-
ically much more effective than total TNF inhibition to
ameliorate the deleterious effects of mechanical ventilation.
Conventional antibody technologies are not optimal for this
purpose for a variety of reasons, perhaps the most important of
which being that monoclonal antibodies to this and, in general,
other cell surface receptors have a tendency to induce receptor
cross-linking, thereby activating rather than inhibiting signal-
ling.16 17 To investigate the possibility of pharmacological inhi-
bition of p55 signalling, we therefore used a novel IgG fragment
known as a domain antibody (GlaxoSmithKline, Stevenage, UK)
that was selected to speciﬁcally bind and inhibit mouse p55
TNF receptor. Domain antibodies (dAbs) comprise the variable
domains of either the heavy or light chain, and are thus
the smallest functional antigen-binding portions of the IgG
molecule.18 19 Domain antibodies offer multiple advantages over
conventional antibody technology: they bind monovalently to
their targets, avoiding the potential for receptor cross-linking;
they lack the Fc portions and do not induce Fc effector responses
such as complement-dependent cytotoxicity or antibody-depen-
dent cytotoxicity; their small size (w12 kD) enables better tissue
penetration, delivery at much higher concentrations per unit mass
and potentially fewer long-term adverse effects (eg, immuno-
suppression) due to more rapid excretion; and they can be
manufactured to be suitable for local delivery such as inhalation.
In this study we investigated the effects of an intratracheally
delivered p55 TNF receptor-targeting dAb in in vivo mouse
models of VILI. We found that selective blockade of intra-alve-
olar p55 signalling reduced alveolar-epithelial barrier perme-
ability and pulmonary inﬂammation, which suggests potential
for new treatments of VILI and ALI.
METHODS
Ventilation protocol
Male C57BL6 mice (Charles River, Margate, UK) aged
8e12 weeks were anaesthetised (intraperitoneal ketamine 80 mg/
kg and xylazine 8 mg/kg), tracheostomised and ventilated using
a custom-made jet ventilator.14 20 21 Airway ﬂow was monitored
by a miniature pneumotach in the ventilator system and tidal
volume (VT) was calculated by integrating ﬂow during inspira-
tion. The left carotid artery was cannulated for blood pressure
(BP) and arterial blood gas (ABG) measurements. Ventilation was
then set to produce VILI (‘pure’ VILI model), standardised by
inspiratory plateau pressure (Pplateau) of 14 cm H2O equating to
VT of w22 ml/kg with positive end-expiratory pressure 3 cm
H2O, respiratory rate 90/min and oxygen+4% carbon dioxide (to
prevent hypocapnia). Immediately afterwards, mice received an
intratracheal bolus of either dummy (non-targeting) dAb or p55-
speciﬁc blocking dAb (25 mg), or either mouse anti-TNF mono-
clonal antibody (50 mg; TN3-19.12; BD Pharmingen, Oxford, UK)
or its isotype control (hamster IgG, BD Pharmingen) in a total
volume of 50 ml. We previously demonstrated the efﬁcacy of the
monoclonal anti-TNF used (with the same route and dose) to
reduce alveolar neutrophil inﬁltration associated with VILI.22 In
a separate series of experiments, a subclinical dose of lipopoly-
saccharide (LPS, 20 ng; Escherichia coli O111:B4, Source Bioscience,
Nottingham, UK) was co-administered intratracheally with the
dAb bolus to enhance the inﬂammatory component of the model.
In this LPS+VILI model, slightly lower Pplateau (13 cm H2O) and
VT (w20 ml/kg) were used as described previously21 because LPS
was expected to enhance the degree of VILI.
Ventilation using the same constant high VTwas continued in
all groups for 240 min or until the mean BP dropped below 45 mm
Hg.14 Anaesthesia was maintained by bolus administrations of
intraperitoneal ketamine:xylazine every 20e25 min. A small
number of animals showed very rapid haemodynamic deteriora-
tion: in the ‘pure VILI’ model, three mice treated with dummy
dAb, one treated with p55-speciﬁc dAb, one treated with isotype
control and two mice treated with anti-TNF; in the LPS +VILI
model, one mouse treated with dummy dAb. These prematurely
terminated experiments were excluded from the analyses. Pplateau,
respiratory system elastance (Ers) and resistance (Rrs) were deter-
mined by the end-inﬂation occlusion technique20 every 20 min,
followed each time by sustained inﬂation (35 cm H2O, 5 s) to
avoid the development of atelectasis. ABG were assessed at
predetermined points throughout the protocol (ﬁgure 1).
Lung lavage
Following termination, lung lavage was performed14 and lavage
ﬂuid was analysed for protein concentration (Bio-Rad Labora-
tories, Hemel Hempstead, UK) and, in some cases, for TNF
levels by ELISA (R&D Systems, Abingdon, UK). In the LPS
+VILI model, levels of interleukin 6 (IL-6), monocyte chemo-
tactic protein 1 (MCP-1), keratinocyte chemoattractant (KC)
and macrophage inﬂammatory protein 2 (MIP-2) in the lavage
ﬂuid were evaluated by ELISA (R&D) and cell pellets were used
for ﬂow cytometry. Cytokine levels are expressed as total
amount (pg) recovered by lavage.
Lung histology
In some experiments, lungs were removed and instilled with 1%
low melting point agarose in 4% paraformaldehyde and
processed for histological evaluation by H&E staining.
Flow cytometry
In the LPS+VILI model, lung single cell suspensions were
prepared from excised lungs by mechanical disruption for ﬂow
cytometry analysis, as described previously.23e25 Lung and lavage
cells were stained with ﬂuorophore-conjugated anti-mouse anti-
bodies for CD11b, CD11c, Gr-1 (Ly6C/G), F4/80 and intercellular
adhesion molecule 1 (ICAM-1) or appropriate isotype-matched
controls, and analysed using a FACSCalibur ﬂow cytometer with
CellQuest (Becton Dickinson, Oxford, UK) and Flowjo (Tree Star,
Ashland, OR, USA) software. Cells were quantiﬁed using
microsphere counting beads (Caltag Medsystems, Towcester,
UK) added to the samples. Activation state of alveolar macro-
phages was evaluated based on surface ICAM-1 expression.
VT 8 ml/kg  
15-20 min 
VT 20-22 ml/kg  
up to 240 min  
Anaesthesia, 
tracheostomy 
Baseline 
readings 
Instillation of 
antibody ± LPS  
bolus 
Instrumentation 
Start of 
injurious 
ventilation 
(ABG) 
120 min 
(ABG) 
End 
(ABG) 
Figure 1 Scheme of ventilation protocol. Mice were anaesthetised,
tracheostomised and ventilated with non-injurious ventilation for
approximately 15e20 min during instrumentation (dotted line). Injurious
ventilation parameters using high tidal volumes (VT) were then introduced,
followed immediately by instillation of the antibody of interest. As a model
of ventilation-induced lung injury with enhanced inflammation, a subclin-
ical dose of lipopolysaccharide (LPS, 20 ng) was co-administered with the
domain antibody bolus. After instillation of the reagents, four sustained
inflations (35 cm H2O, 5 s) were applied to help the fluid distribute within
the lungs. Respiratory mechanics were assessed every 20 min, followed
each time by sustained inflation. Arterial blood gases (ABG) were
assessed at predetermined time points (start, 120 min, end).
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Statistical analysis
Data are expressed as mean6SD. Statistical comparisons were
made by two-way repeated measures ANOVA for time course
data or unpaired t tests for end point data using Prism software
Version 5.0. A value of p<0.05 was considered signiﬁcant. For
some end point analyses, data were compared with those of
non-ventilated mice for qualitative purposes.
RESULTS
Effects of anti-p55 domain antibody on respiratory physiology in
the ‘pure’ VILI model
Mechanical ventilation with the high stretch protocol caused
a substantial deterioration in lung function in dummy dAb-
treated animals, consistent with pulmonary oedema formation.
This was represented by a rapidly increasing Pplateau, Ers and Rrs
that occurred towards the end of the 4 h ventilation protocol
(ﬁgure 2AeC). In marked contrast, no deteriorations were seen
in respiratory mechanics in the p55 dAb group.
Arterial oxygen and carbon dioxide tensions (PO2 and PCO2)
were similar between the two groups at the start and 120 min
after drug instillation (ﬁgure 2E,F). By the end of the protocol,
oxygenation tended to deteriorate in dummy dAb-treated
animals (3656146 mm Hg) while PCO2 increased. In contrast,
PO2 was better maintained in the p55 dAb group (440641 mm
Hg) and PCO2 was unchanged from the 120 min level. To assess
alveolar epithelial permeability we measured the protein content
in lavage ﬂuid. VILI resulted in substantial protein levels in the
dummy dAb group compared with non-ventilated controls
(2.8261.73 vs 0.2160.03 mg/ml), and this was signiﬁcantly
attenuated in mice given the p55 dAb (1.3460.4 mg/ml,
ﬁgure 2H). TNF levels in bronchoalveolar lavage ﬂuid evaluated
at the end of the ventilation protocol in the dummy dAb group
were found to be upregulated (1476144 pg, n¼11) compared
with untreated mice (less than the assay detection limit of
15 pg/ml).
Lung histology indicated a moderate degree of injury after
VILI with dummy dAb treatment, characterised by neutrophil
inﬁltration and proteinaceous material in the alveolar space
(ﬁgure 3A,B) that was substantially reduced following p55 dAb
(ﬁgure 3C,D).
Effects of anti-TNF monoclonal antibody on respiratory
physiology during VILI
Having found that blockade of p55 TNF receptor signalling
attenuated VILI, we investigated whether total TNF blockade
would be similarly efﬁcacious. To address this, we treated mice
with anti-TNF monoclonal antibody (or isotype control) using
the same instillation strategy and ventilation protocol as for the
dAb experiments.
We found that changes in respiratory mechanics in the isotype
control-treated group followed a very similar pattern as was
observed for the dummy dAb group (ﬁgure 4AeC). In marked
contrast to the beneﬁcial effect of the p55-speciﬁc dAb, however,
the anti-TNF monoclonal antibody did not attenuate the
changes seen in isotype-treated animals. Similarly, anti-TNF
treatment had no beneﬁcial effect on blood gases (ﬁgure 4EeG)
or alveolar epithelial permeability (ﬁgure 4H).
Effects of anti-p55 domain antibody on inflammation following
LPS+VILI
Finally, we evaluated whether the p55-speciﬁc dAb would also
have a beneﬁcial effect on pulmonary inﬂammation during VILI.
Our group and others26 have shown that pure mechanical
Figure 2 (A) Plateau pressure (Pplateau), (B) respiratory system
elastance (Ers), (C) respiratory system resistance (Rrs), (D) mean arterial
pressure, (E) arterial oxygen tension (PO2), (F) arterial carbon dioxide
tension (PCO2), (G) bicarbonate (HCO3
) and (H) lavage fluid protein
were determined in ventilated animals treated intratracheally with either
dummy or p55-specific domain antibody (dAb). Changes in Ers and Rrs
are expressed as percentage increase in relation to Start (before
instillation) values. Pplateau, Ers and Rrs changes over time during
ventilation were significantly different between treatment groups
(#p<0.05 for interaction between treatment and ventilation time by
two-way ANOVA). Arterial PO2 showed a tendency to deteriorate in
animals treated with the dummy dAb but not in mice given the p55-
specific dAb. Changes in PCO2 over time were significantly different
between treatment groups (#p<0.05 for interaction by two-way
ANOVA), while changes in bicarbonate levels were similar across
groups. Lavage fluid protein was significantly attenuated in the p55-
specific dAb group (*p<0.05 by unpaired t tests). The dotted line
represents the mean value in non-ventilated control animals (N¼8e11
per group).
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ventilation induces a relatively limited degree of alveolar
neutrophil inﬁltration (within the time frame of ventilation
used currently), one of the hallmarks of clinical ALI. We there-
fore included a ‘subclinical’ dose of LPS (20 ng) mixed with the
dummy or p55-speciﬁc dAbs at the start of mechanical venti-
lation to enhance the degree of inﬂammation within the model.
Preliminary studies demonstrated that this dose of LPS did not
induce changes in respiratory mechanics with low tidal volume
ventilation.
As with the ‘pure’ VILI model, LPS+VILI induced substantial
changes in respiratory mechanics which were signiﬁcantly
attenuated by treatment with p55-speciﬁc dAb (ﬁgure 5AeC).
Similarly, administration of the p55 dAb prevented the deterio-
ration of oxygenation (ﬁgure 5E) and tended to attenuate the
rise in PCO2 (ﬁgure 5F). p55 dAb also tended to decrease protein
levels in lavage ﬂuid (2.9461.62 vs 2.0661.45 mg/ml for dummy
and p55 dAb, respectively), although this did not reach statis-
tical signiﬁcance (ﬁgure 5H).
Leucocyte subsets in lung single cell suspension and lavage
ﬂuid were identiﬁed based on characteristic antigen expression
using ﬂow cytometry (ﬁgure 6AeC) and their number or acti-
vation state was quantitatively assessed. LPS+VILI increased
the number of lung-recruited neutrophils compared with non-
ventilated controls (2.3260.573106 vs 0.1360.053106), which
was signiﬁcantly attenuated by the p55-speciﬁc dAb
(1.2560.313106, p<0.01 vs dummy; ﬁgure 6A). A similar trend
was found with margination of inﬂammatory subset Gr-1high
monocytes, although this was not signiﬁcant (ﬁgure 6A).
Transmigration of neutrophils to the alveolar space was also
greatly increased by LPS+VILI and substantially attenuated by
p55 dAb treatment (ﬁgure 6B). Alveolar macrophages in lavage
ﬂuid of dummy dAb-treated mice showed increased expression
of ICAM-1 compared with non-ventilated controls, indicative of
activation,27 which was also reduced in the p55 dAb group
(ﬁgure 6C). Finally, treatment with p55 dAb signiﬁcantly
decreased IL-6 and MCP-1 in lavage ﬂuid, with similar trends for
KC and MIP-2 (ﬁgure 7).
DISCUSSION
ALI and ARDS are characterised by pulmonary oedema, hypo-
xaemia and inﬂammation. While mechanical ventilation is an
essential aspect of treatment, this can exacerbate underlying
lung injury and cause VILI. It has been suggested that this can
progress to systemic inﬂammation and multiple system organ
failure, which is a major cause of death among patients with
ARDS.28 29 Although mortality is improved by the use of low
tidal volume ventilation in conjunction with other interven-
tions, it is not possible to eliminate completely the consequences
of VILI in this manner. An ideal therapeutic agent would
therefore attenuate both the respiratory dysfunction which
drives the requirement for ventilation and the inﬂammatory
response which may ultimately lead to death. In this study we
investigated the use of a novel therapeutic technologyddomain
antibodiesdfor the ﬁrst time in the area of ALI, and showed
that intratracheal administration of dAb targeting the p55 TNF
receptor attenuated the development of VILI.
Using a mouse model of ‘pure’ VILI we found that deterio-
rations in respiratory function and alveolar-epithelial barrier
permeability were substantially improved when p55-speciﬁc
blocking dAb was given intratracheally at the start of the
ventilation protocol. In complete contrast, intratracheal
administration of a monoclonal anti-TNF antibody did not
attenuate stretch-induced respiratory dysfunction. In addition,
in an LPS+VILI model incorporating a greater degree of
pulmonary inﬂammation, administration of the p55-speciﬁc
dAb led to decreased levels of the proinﬂammatory cytokine IL-6
and the monocyte/neutrophil chemoattractant MCP-1 in lavage
ﬂuid, and showed strong trends towards decreases in the
Figure 3 Photomicrographs of lung
tissue. Sample from dummy domain
antibody (dAb)-treated mouse (A, B)
showed marked cellularity, alveolar wall
thickening (arrow), hyaline membrane
formation and intra-alveolar debris
(arrowhead) whereas minimal changes
were seen in p55 dAb-treated mouse
(C, D). H&E stain. Magnification 3100
(A and C), 3400 (B and D).
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chemokines MIP-2 and KC. While the precise sources of these
inﬂammatory mediators in VILI remain uncertain, alveolar
macrophages are likely contributors and, indeed, we observed
that alveolar macrophage activation (surface ICAM-1 expres-
sion27) was signiﬁcantly attenuated by dAb treatment.
Presumably as a consequence of this reduced intra-alveolar
inﬂammation, margination and migration of neutrophils
within the lung was also attenuated. These data demonstrate
clearly that speciﬁc blockade of p55 TNF-receptor signalling
within the alveolar space attenuates multiple markers of VILI
development.
Figure 4 (A) Plateau pressure (Pplateau), (B) respiratory system
elastance (Ers), (C) respiratory system resistance (Rrs), (D) mean arterial
pressure, (E) arterial oxygen tension (PO2), (F) arterial carbon dioxide
tension (PCO2), (G) bicarbonate (HCO3
) and (H) lavage fluid protein
were not significantly different between animals treated intratracheally
with either isotype or mouse anti-tumour necrosis factor (TNF)
monoclonal antibody (mAb). Dotted line represents mean value in non-
ventilated control animals (N¼6 per group).
Figure 5 (A) Plateau pressure (Pplateau), (B) respiratory system
elastance (Ers) and (C) resistance (Rrs), (D) mean arterial pressure, (E)
arterial oxygen tension (PO2), (F) arterial carbon dioxide tension (PCO2),
(G) bicarbonate (HCO3
) and (H) lavage fluid protein of dummy domain
antibody (dAb)-treated and p55 dAb-treated mice in the lipopolysaccha-
ride + ventilation-induced lung injury (LPS+VILI) model. Changes in Ers
and Rrs are expressed as percentage increase in relation to Start values.
Changes in Pplateau, Ers, Rrs, arterial PO2 and bicarbonate over time were
significantly different between treatment groups (#p<0.05 for interaction
between treatment and ventilation time by two-way ANOVA). The p55-
specific dAb tended to attenuate the rise in PCO2, but this did not reach
statistical significance (p¼0.055 for interaction by two-way ANOVA).
Lavage fluid protein levels tended to be reduced in p55-specific dAb-
treated animals, but not significantly. The dotted line represents the mean
value in non-ventilated controls (N¼8e11 per group).
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The ventilation parameters used within this study (VT
20e22 ml/kg), although higher than used clinically in humans,
would have induced only a moderately high degree of lung
stretch in untreated healthy mice as mouse lungs are much more
compliant than those of humans.30 However, due to the impact
of the intratracheal ﬂuid instillation, such settings were sufﬁ-
cient to induce injury within 4 h of ventilation. While the
timeframe of the current experiment is much shorter than
patients with ALI would be ventilated, it is comparable with the
majority of published rodent studies of VILI and ALI. Sustained
inﬂations and post end-expiratory pressure were used
throughout the ventilation protocols as mouse lungs have a very
high tendency for atelectasis even at such VT, which could have
substantial confounding effects. Since atelectasis was minimised
by these recruitment measures, the major component of the
observed physiological changes can be ascribed to the develop-
ment of stretch-induced pulmonary oedema. The dAb was given
immediately after setting ventilation parameters in order to
allow robust standardisation of the VILI protocol, avoiding
the unpredictable inﬂuence of instillation on respiratory
mechanics (upon which the degree of VILI was standardised).
The ﬁnding that pulmonary oedema and inﬂammation during
VILI were attenuated under these conditions would indicate
that a substantial prophylactic period was unnecessary for dAb
efﬁcacy.
From the current data it is not possible to determine precisely
why the p55-speciﬁc dAb was clearly more effective in attenu-
ating VILI than the anti-TNF monoclonal antibody. One possi-
bility is that greater efﬁcacy of the dAb was related to its
biophysical propertiesdits small size (w12 kDa compared to
w150 kDa for IgG) and monovalent target antigen binding
allows more potency per unit mass, greater tissue penetration
and better biodistribution, and reduced risk of receptor cross-
linking and activation compared with conventional antibody
technology. Thus, despite the fact that we used a 23 larger
amount (in terms of weight) of the monoclonal antibody, the
dAb could be delivered at an approximately 63 greater dose than
the monoclonal antibody which may simply induce more
effective inhibition of TNF receptor binding. This lack of efﬁcacy
of anti-TNF treatment to attenuate the physiological manifes-
tations of VILI are somewhat at odds with a previous study
showing a positive effect of anti-TNF in a rabbit model of saline
Figure 6 Flow cytometric analysis of
leucocyte subsets in the lungs and
lavage fluid of dummy domain antibody
(dAb)-treated and p55 dAb-treated
mice in the lipopolysaccharide +
ventilation-induced lung injury (LPS
+VILI) model. (A) In lung single-cell
suspensions, monocytes were
identified as CD11b+, F4/80+ events,
and their subsets were defined as either
Gr-1low (R1) or Gr-1high (R2),
differentiated from CD11b+, F4/80,
Gr-1very high neutrophils (R3). (B)
Neutrophils in lavage fluid were
similarly identified as CD11b+, F4/80,
Gr-1very high events (R4), whereas
monocytes were not present. (C)
Alveolar macrophages in lavage fluid
were recognised as forward/side
scatterhigh, F4/80+, CD11c+ events
(R5) and their intercellular adhesion
molecule (ICAM-1) expression was
quantitatively assessed (mean
fluorescence intensity (MFI) after
isotype subtraction). The dotted line
represents the mean value in non-
ventilated control animals. *p<0.05,
**p<0.01 by unpaired t test (N¼8e11
per group).
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lavage followed by injurious ventilation,4 but do reﬂect the
disappointing results from clinical trials in patients with
sepsis/ARDS.7e10 31
In addition to the biophysical properties of the respective
antibodies, we believe target antigen speciﬁcity is vitally
important. Despite the large number of studies investigating
TNF as a potential therapeutic agent, the complexity of TNF
biology remains rather poorly appreciated. It has been assumed
that the majority of TNF signalling occurs through the p55
receptor, with p75 playing only an auxiliary role, but it is
becoming clearer that the two receptors can signal indepen-
dently and, in some cases, may exert directly opposite effects to
each other.11 15 For example, we previously showed using knock-
out mice that signalling through p55 promoted the development
of high stretch-induced pulmonary oedema, while signalling
through p75 protected against oedema formation during VILI,
and that these opposing effects seemed to be independent of
TNF-mediated leucocyte recruitment.15 Such was the nature of
this opposing signalling that mice devoid of all TNF receptors
showed no protection from oedema (a ﬁnding consistent with
others32). These data from genetically modiﬁed animals suggest
that non-selective anti-TNF treatment would not be effective
however high a dose of antibody we may be able to deliver.
Interestingly, in an earlier study we showed that the monoclonal
anti-TNF antibody used currently attenuated neutrophilic
alveolitis in VILI.22 Similarly, Wolthuis et al found that total
blockade of TNF signalling by etanercept, a p75 receptor-Fc
fusion protein, failed to attenuate high stretch-induced pulmo-
nary oedema but had some positive effects on inﬂammation.33
Taken together, these data suggest that, while treatment
designed to block TNF per se may be effective in reducing
pulmonary inﬂammation associated with VILI, it has little
impact on pulmonary oedema, presumably as any beneﬁcial
effects of signalling through the p75 receptor on pulmonary ﬂuid
balance are inhibited. The nature of these beneﬁcial effects of
p75 signalling remains unclear, but we speculate that it may
involve actin cytoskeleton rearrangements34 35 or prevention of
epithelial/endothelial apoptosis.12
In conclusion, we have shown for the ﬁrst time that speciﬁc
and selective pharmacological inhibition of intra-alveolar TNF
receptor p55 signalling by a dAb can ameliorate pulmonary
oedema and inﬂammation during VILI in mice. Targeting intra-
alveolar TNF receptor p55 signalling may open new therapeutic
approaches for ventilated patients with ALI.
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